In a meta-analysis, the pooled relative risks (RRs) for prostate cancer were 4.35 and 1.18 for non-Ashkenazi European ancestry BRCA2 and BRCA1 GPV carriers, respectively [54]. This evidence concerns the gene BRCA1 and Familial prostate cancer.